Nevertheless, results from these trials will inform the greater clinical community whether diet may be a viable therapeutic strategy, either alone or in conjunction with pre-existing IGF-1R-targeting therapies, for breast cancer patients. The gene discussed is IGF1R; the disease is breast cancer.